Case Report: The many faces of bullous pemphigoid.
COVID-19 vaccination
bullous autoimmune disease
bullous pemphigoid
juvenile pemphigoid
pemphigoid gestationis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
08
2023
accepted:
12
09
2023
medline:
31
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
The pemphigoid group comprises a number of bullous skin diseases with autoantibodies against different constituents of the basement membrane zone that result in subepidermal detachment and clinically characteristic tense blisters, erosions, urticarial erythema, and itching. Apart from the most frequent type of bullous pemphigoid with antibodies against BP180, which is found predominantly in elderly patients, the disease may present at other ages and different pathogenic conditions. Here, four cases are presented of young age (3 months and 25, 34, and 46 years) and in association with vaccination, pregnancy, or metastatic cancer. Though anti-BP180 was found in all cases, a different pathogenic background may be found in any of them, resulting in characteristic clinical manifestation, yet demanding specifically adapted therapeutic approaches.
Identifiants
pubmed: 37901243
doi: 10.3389/fimmu.2023.1272742
pmc: PMC10601641
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1272742Informations de copyright
Copyright © 2023 Rechtien, Sollfrank, Foerster, Berking and Sticherling.
Déclaration de conflit d'intérêts
MS has performed clinical studies on bullous pemphigoid sponsored by Sanofi and Argenx. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Acad Dermatol. 2021 Jul;85(1):79-87
pubmed: 33744354
J Dermatol Sci. 2007 Jul;47(1):1-7
pubmed: 17467241
J Am Acad Dermatol. 2021 Jan;84(1):194-196
pubmed: 32335181
Clin Dermatol. 2016 May-Jun;34(3):378-82
pubmed: 27265076
Br J Dermatol. 2010 Nov;163(5):1120-2
pubmed: 20586779
J Dtsch Dermatol Ges. 2018 Sep;16(9):1077-1091
pubmed: 30179336
An Bras Dermatol. 2013 Nov-Dec;88(6):961-5
pubmed: 24474106
Hautarzt. 2017 Feb;68(2):87-94
pubmed: 28074212
Pediatr Dermatol. 2015 Nov-Dec;32(6):845-52
pubmed: 26391853
Br J Dermatol. 2022 Apr;186(4):737-739
pubmed: 34842282
Am J Clin Dermatol. 2017 Feb;18(1):105-126
pubmed: 27878477
Autoimmun Rev. 2017 May;16(5):445-455
pubmed: 28286109
Arch Dermatol Res. 2014 Jan;306(1):75-80
pubmed: 23912480
J Dtsch Dermatol Ges. 2020 May;18(5):516-527
pubmed: 32413222
J Am Acad Dermatol. 2022 May;86(5):1160-1164
pubmed: 33905786
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e412-e414
pubmed: 33655539
JAAD Case Rep. 2020 Sep 09;6(11):1173-1178
pubmed: 33145386
Front Med (Lausanne). 2021 Dec 20;8:807711
pubmed: 34988105
Br J Dermatol. 2021 Jan;184(1):68-77
pubmed: 32147814
Dermatol Ther. 2022 Jan;35(1):e15208
pubmed: 34786801
Br J Dermatol. 2022 Oct;187(4):606-607
pubmed: 35531603
World J Clin Cases. 2021 Dec 6;9(34):10645-10651
pubmed: 35004996
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e13-e16
pubmed: 34547137
Br J Dermatol. 2022 Aug;187(2):271-273
pubmed: 35279833
J Am Acad Dermatol. 2021 Feb;84(2):563-568
pubmed: 32781181
J Allergy Clin Immunol. 2021 Sep;148(3):750-751
pubmed: 34275656